



18 September 2014

Sinclair IS Pharma plc

Directorate Changes

Distribution Agreement with Amicus SA

Sinclair IS Pharma plc (AIM: SPH.L) ("Sinclair" or "the Group"), the international specialty pharmaceutical company, announces the resignation, with immediate effect, of Stuart Swanson as a non-executive director. After serving on the Board for nearly three years, Stuart is departing in order to concentrate on the launch of his new pharmaceutical company, Amicus SA ('Amicus'). The Board is indebted to him for his involvement during a period of rapid growth and change at Sinclair as the business shifted strategic focus towards the Aesthetic Dermatology market. Stuart remains a notable private shareholder of Sinclair, and his new company, Amicus, has signed a 5 year contract to represent Sinclair's complete aesthetic portfolio in certain Balkan territories. CEO Chris Spooner commented:

"On behalf of the Sinclair Board, I would like to thank Stuart personally for his invaluable contribution. Moreover the impact of Stuart's dermatology and emerging market experience extended beyond the Board room and as such he is held in the highest regard by many in the Company. We are pleased that Stuart's relationship with Sinclair IS will continue, albeit in a different form, as he and his new company will be representing our exciting portfolio of aesthetic dermatology products in the Balkans. I have no doubt we will remain in close contact and I wish him every success in his exciting new venture".

Stuart Swanson commented:

It has been an honour to serve on the Sinclair IS Board and I hope that I have contributed, in some small way, to the development of this fine company. I have learned a great deal, and particularly regret leaving the company when it is self-evidently at an inflection point. The newly-acquired stable of aesthetic products shows great promise. In addition, both the continued rationalisation of the portfolio and the Company's strategic focus on emerging markets should pay strong returns for shareholders in the years ahead. I wish Chris, the Board and his fine management team every success for the future."

Sinclair announces the immediate appointment of Jeff Thompson as a non-executive director. US-based Mr Thompson is a partner of HealthEdge Investment Partners LLC, a Tampa, Florida based US specialist healthcare private equity fund. He has many years of experience in the US dermatology industry having served on the Board of Directors for, and as COO, of Stiefel Laboratories, Inc., the world's largest privately held Dermatology company with over \$900 Million of revenue, prior to its acquisition by GlaxoSmithKline plc, and currently holds various directorships including President/CEO/Chairman of Enaltus (dermatology, pvt) and non-executive director of Anika Therapeutics, Inc. a US publicly traded and (NASDAQ: ANIK) Bedford, Massachusetts based biotechnology company that develops, manufactures and commercializes hyaluronic acid based products. With the US developments of Silhouette®, Ellansé™ and Flammacerium® underway, Sinclair has a strategic objective of entering the US market and believes Mr Thompson's appointment will be invaluable in helping achieve this aim. CEO Chris Spooner commented:

"We welcome Jeff to the Sinclair Board. Jeff has worked closely with Sinclair for several years and brings a wealth of industry and US-specific experience and knowledge. As we expand our direct US presence beyond Silhouette-Lift®, the Board felt it was essential recruit a non-executive with US operational experience. Jeff's track record speaks for itself and we are delighted he has become part of our team".

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Mr Jeffery Scott Thompson, age 48 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships:

Anika Therapeutics, Inc. (2011-Current)
Advanced Bio-Technologies, Inc. (2008-Current)
Lifesync Corp. (2012-Current)
ABT-Belli Materna, Inc. (2008-Current)

Current Manager or Partner:

Infinity Home Care, LLC (2011-Current)
Enaltus, LLC (2011-Current)
MedAltus, LLC (2012-Current)
Strait & Level Enterprises, LLC (2011-Current)
Puristics, LLC (2012-Current)
Refine, LLC (2011-Current)

HealthEdge Investment Partners Fund II, LLP (2011-Current)

Past directorships:

Woodbury Acquisition Corp. (2008-2012)

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

Amicus SA Signs 5 Year Representation - Distribution Contract with Sinclair IS Pharma for non-EU ex-Yugoslav Territory

Amicus SA of Zug, Switzerland has signed a five year representation and distribution contract (the 'Contract') to represent Sinclair's path-breaking new Aesthetic Derma products (Ellansé™, Kelo-cote®, Perfectha® and Silhouette®) in five countries: Serbia, Bosnia, Kosovo, Macedonia and Montenegro. First launches are expected in Serbia in January 2015; registration of the Sinclair portfolio is already underway. There are no upfront payments or licensing fees paid upon signing the Contract.

The Contract constitutes a Related Party Agreement under Rule 13 of the AIM Rules for Companies. The Directors, having consulted with Peel Hunt, believe the terms of the Contract are fair and reasonable insofar as the shareholders are concerned.

For further information, please contact:

Sinclair IS Pharma plc

Chris Spooner

Alan Olby

Tel: +44 (0) 20 7467 6920

Peel Hunt LLP

James Steel

Clare Terlouw

Tel: +44 (0) 20 7418 8900

Notes for editors:

About Sinclair IS Pharma plc - see www.sinclairispharma.com

Sinclair IS Pharma is an international specialty pharmaceutical company centred on Dermatology, in particular Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.

About Amicus: Amicus subsidiaries operate in the Balkan countries of Serbia, Bosnia, Kosovo, Macedonia, Montenegro, as well as Croatia and Slovenia. Set up in 2014 by Petr Nemeč and Stuart Swanson, the founders of PharmaSwiss SA (sold to Valeant International in 2011), Amicus has gathered a brain trust of outstanding pharmaceutical talent, including long experience in aesthetic dermatology in the region. The company's mission is to play a part in resolving unmet pharmaceutical and medical device needs swiftly and in a cost effective manner. Amicus has the ability to provide expertise, knowledge and rapid execution - as well as a mandate to attract novel products to an under-served market.

This information is provided by RNS
The company news service from the London Stock Exchange

END

BOABIGDCBUBBGSR